On the stock market since 2009, it operates in the world of health and science. It has 17,995 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (5% a year).
The gap is $3.8B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 15% below its peak. The market has trimmed its expectations for the company.
It pays out $3.19 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The company’s market value is 53 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, LZAGF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LZAGF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.